Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Keratoconus

  • Author: Barry A Weissman, OD, PhD, FAAO; Chief Editor: Hampton Roy, Sr, MD  more...
 
Updated: Apr 21, 2016
 

Practice Essentials

Keratoconus (KC) is a progressive, noninflammatory, bilateral (but usually asymmetric) ectatic corneal disease, characterized by paraxial stromal thinning and weakening that leads to corneal surface distortion. Visual loss occurs primarily from irregular astigmatism and myopia, and secondarily from corneal scarring. See the image below.

An optic section of a keratoconic cornea shows cor An optic section of a keratoconic cornea shows corneal thinning. Vogt striae and some scarring can also be seen centrally; superiorly, a small (brown) section of the Fleischer ring is noted.
The fluorescein pattern of a rather flat-fitted ri The fluorescein pattern of a rather flat-fitted rigid contact lens on an advanced keratoconic cornea.

Signs and symptoms

Patients with keratoconus may report the following:

  • Distortions
  • Glare/flare
  • Monocular diplopia or ghost images
  • Multiple unsatisfactory attempts to obtain optimum spectacle correction
  • Itchy eyes

Keratoconus is differentiated into mild, moderate, and advanced cases.

Characteristics of mild keratoconus may include the following:

  • Absent or minimal external and corneal signs
  • Oblique astigmatism on refraction; moderate-to-high myopia
  • Irregular astigmatic keratometry values
  • Corneal inferior steepening, central corneal astigmatic steepening, or bilateral temporal steepening on computer-assisted videokeratography
  • Typical nipple pattern with the application of a diagnostic rigid contact lens

Characteristics of moderate keratoconus may include the following:

  • Presence of one or more corneal signs of keratoconus (eg, enhanced appearance of corneal nerves, Vogt striae, Fleischer ring, corneal scarring)
  • Superficial corneal scarring (fibular, nebular, or nodular)
  • Deep stromal scarring
  • Scarring at the level of the Descemet membrane resembling posterior polymorphous corneal dystrophy
  • Paraxial stromal thinning as seen on corneal optical coherence tomography (OCT) pachymetry with biomicroscope slit-lamp examination
  • Keratometry values of 45-52 diopters (D)
  • “Scissoring” or the oil drop sign
  • Munson sign

Characteristics of advanced keratoconus may include the following:

  • Keratometry values greater than 52 D
  • Enhancement of all corneal signs, symptoms, and visual loss/distortion
  • Vogt striae; Fleischer ring and/or scarring
  • Acute corneal hydrops

See Presentation for more detail.

Diagnosis

No laboratory workup is necessary.

Diagnostic measures that may yield evidence of keratoconus include the following:

  • Refraction
  • Slit-lamp biomicroscopy
  • Rigid gas-permeable (GP) contact lens application
  • Keratometry
  • Videokeratography
  • OCT pachymetry

Rabinowitz diagnostic criteria for keratoconus include the following 3 videokeratography-derived indices and OCT pachymetry measurements (inferior-superior [I-S] value and minimum pachymetry) which, when abnormal, suggest the diagnosis:

  • K value - Measures central steepening of the cornea; a value of 47.20 D or greater suggests keratoconus
  • I-S value - Measures inferior-versus-superior corneal dioptric asymmetry; a value of 1.4 D or greater suggests keratoconus
  • KISA% - Incorporates K and I-S values with a measure quantifying regular and irregular astigmatism into a single index; a value in the range of 60-100% suggests keratoconus, and a value exceeding 100% strongly suggests frank keratoconus
  • Pachymetry/asymmetry (PA)/I-S index - The minimum pachymetry value divided by the I-S value ; identifies keratoconus suspects and forme fruste keratoconus when the PA/I-S index is less than 105

See Workup for more detail.

Management

Nonsurgical treatment measures include the following:

  • Rigid contact lenses or scleral lenses (mainstay of therapy) - Patients with early keratoconus may successfully use spectacles or spherical/toric soft contact lenses; those with moderate-to-advanced keratoconus almost always require rigid contact lenses
  • Corneal collagen cross-linking

Although no direct pharmacologic management is available, the following agents may be useful aids:

  • Nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Antihistamines
  • Mast cell stabilizing topical medications
  • Ophthalmic cyclosporine
  • Steroid drops
  • Hyperosmotic agents
  • Topical antibiotics

Surgical options include the following:

  • Superficial keratectomy with a blade
  • Excimer laser phototherapeutic keratectomy
  • Implantation of intrastromal corneal rings (better for moderate than for advanced disease)
  • Bowman layer transplantation
  • Deep anterior lamellar keratoplasty (DALK)
  • Penetrating keratoplasty (PKP)

See Treatment and Medication for more detail.

Next

Background

Keratoconus is a progressive, noninflammatory, bilateral (but usually asymmetric) ectatic corneal disease, characterized by paraxial stromal thinning and weakening that leads to corneal surface distortion. Visual loss occurs primarily from irregular astigmatism and myopia, and secondarily from corneal scarring.

Previous
Next

Pathophysiology

All layers of the cornea are believed to be affected by keratoconus, although characteristic structural changes include epithelial basement membrane fragmentation and scarring and breaks in the anterior limiting lamina (ie, Bowman membrane), with axial stromal thinning and scarring. Deposition of iron in the basal epithelial cells forms the Fleischer ring. Breaks in and folds close to the Descemet membrane result in acute hydrops rarely and striae commonly, respectively.

The literature on keratoconus is large and contradictory regarding the roles of disruption of collagen fibers, lamellae, and proteoglycans in the disease; however, keratoconic corneas have been shown to have altered antioxidant enzymes, accumulations of cytotoxic reactive oxygen/nitrogen species, activated caspase pathways, and mitochondrial DNA damage. Abnormal oxidative stress-related properties have been found in keratoconic corneal cells. Oxidative stress elements can induce activation of degradative enzymes and degradation of tissue inhibitors of metal-low proteinases. Genomic deletion in the superoxide dismutase 1 (SOD1) gene has also been associated with the disease.[1, 2, 3, 4, 5]

Although usually believed to be noninflammatory, some data suggest an inflammatory component.[6, 7]

Previous
Next

Frequency

United States

Reported prevalence in the general population varies (50-200 cases per 100,000 population), perhaps with differences in diagnostic criteria. It is commonly an isolated ocular condition but sometimes coexists with other ocular and systemic diseases.[8, 4, 9]

Commonly recognized ocular associations include vernal keratoconjunctivitis, retinitis pigmentosa, and Leber congenital amaurosis; systemic putative associations include many of the connective tissue disorders (eg, Ehlers-Danlos and Marfan syndromes), mitral valve prolapse, atopic dermatitis, and Down syndrome, although this was not found in the Collaborative Longitudinal Evaluation of Keratoconus (CLEK) study.[10]

Particular risk factors include atopic history, especially ocular allergies, and perhaps either or both rigid contact lens wear, and vigorous eye rubbing.[8, 11, 9, 12, 13]

Most keratoconus cases appear spontaneously, although approximately 14% of cases present with evidence of genetic transmission.[12]

The prevalence of keratoconus varies by ethnicity. Keratoconus is more common in blacks and Latinos than in whites, with odds ratios of 1.57 and 1.43, respectively. It is less common in Asians than in whites, with an odds ratio of 0.61.[14]

Personal income/access to health care and education levels have no known correlation with keratoconus.[14]

International

Anecdotal reports suggest an increase in prevalence in some parts of the world, Arabia, the Indian subcontinent, and New Zealand.

Previous
Next

Mortality/Morbidity

Because few elderly patients have been noted with keratoconus, many wonder if keratoconus is associated with a fatal disease. However, several studies provide compelling evidence that keratoconus does not result in increased mortality.[15]

Advanced keratoconus may rarely progress to corneal hydrops, so-called "acute keratoconus," wherein breaks occur in the Descemet layer that cause aqueous to enter the stroma, leading to central stromal edema and potentially secondary severe corneal scarring. Patients report sudden loss of vision and some ocular discomfort in one eye but usually not much pain or conjunctival injection. Acute treatment of hydrops is palliative; many corneas flatten secondary to hydrops, and both visual acuity and contact lens application may improve following such events. If secondary scarring is severe, corneal transplantation (PKP) may be warranted.

Corneal surgery is otherwise indicated when contact lenses are either no longer tolerated or no longer useful in vision correction. When good contact lens care is available, only 10-20% of patients with keratoconus eventually require PKP.[16] The need for PKP increases when optimal contact lens care is not available, but many patients still require contact lens care for optimum visions following PKP.

DALK is gaining popularity as an option.[17, 18] Other surgical treatments include removal of superficial nodular scars, implantation of plastic ring segments in the cornea (intrastromal corneal rings [ICRS]), Bowman layer transplantation, and ultraviolet collagen cross-linking (UV-CXL), which may be combined with other procedures.[19, 20, 21, 22]

Sex

Early literature suggested that keratoconus was autoimmune in origin and therefore more likely to affect females. However, recent studies have suggested that keratoconus may be more common in males.[14]

Age

Keratoconus typically presents at puberty and progresses until the third and fourth decades of life, although it can occur or progress at any age. Keratoconus progresses at various rates but tends to progress more rapidly in young patients and stabilizes approximately 20 years after initial onset.[23]

Previous
 
 
Contributor Information and Disclosures
Author

Barry A Weissman, OD, PhD, FAAO Professor of Optometry, Southern California College of Optometry; Professor Emeritus of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Barry A Weissman, OD, PhD, FAAO is a member of the following medical societies: American Academy of Optometry, American Optometric Association, California Optometric Society, International Society for Contact Lens Research

Disclosure: Nothing to disclose.

Coauthor(s)

Karen K Yeung, OD, FAAO Senior Optometrist, Arthur Ashe Student Health and Wellness Center, University of California, Los Angeles

Karen K Yeung, OD, FAAO is a member of the following medical societies: American Academy of Optometry

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Christopher J Rapuano, MD Professor, Department of Ophthalmology, Jefferson Medical College of Thomas Jefferson University; Director of the Cornea Service, Co-Director of Refractive Surgery Department, Wills Eye Hospital

Christopher J Rapuano, MD is a member of the following medical societies: American Academy of Ophthalmology, American Ophthalmological Society, American Society of Cataract and Refractive Surgery, Contact Lens Association of Ophthalmologists, International Society of Refractive Surgery, Cornea Society, Eye Bank Association of America

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Cornea Society, Allergan, Bausch & Lomb, Bio-Tissue, Shire, TearScience, TearLab<br/>Serve(d) as a speaker or a member of a speakers bureau for: Allergan, Bausch & Lomb, Bio-Tissue, TearScience.

Chief Editor

Hampton Roy, Sr, MD Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy, Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

Additional Contributors

Fernando H Murillo-Lopez, MD Senior Surgeon, Unidad Privada de Oftalmologia CEMES

Fernando H Murillo-Lopez, MD is a member of the following medical societies: American Academy of Ophthalmology

Disclosure: Nothing to disclose.

References
  1. Rabinowitz YS. Keratoconus. Surv Ophthalmol. 1998 Jan-Feb. 42(4):297-319. [Medline].

  2. Kennedy RH, Bourne WM, Dyer JA. A 48-year clinical and epidemiologic study of keratoconus. Am J Ophthalmol. 1986 Mar 15. 101(3):267-73. [Medline].

  3. Critchfield JW, Calandra AJ, Nesburn AB, Kenney MC. Keratoconus: I. Biochemical studies. Exp Eye Res. 1988 Jun. 46(6):953-63. [Medline].

  4. Sawaguchi S, Yue BY, Sugar J, Gilboy JE. Lysosomal enzyme abnormalities in keratoconus. Arch Ophthalmol. 1989 Oct. 107(10):1507-10. [Medline].

  5. Gondhowiardjo TD, van Haeringen NJ. Corneal aldehyde dehydrogenase, glutathione reductase, and glutathione S-transferase in pathologic corneas. Cornea. 1993 Jul. 12(4):310-4. [Medline].

  6. Sawaguchi S, Twining SS, Yue BY, et al. Alpha 2-macroglobulin levels in normal human and keratoconus corneas. Invest Ophthalmol Vis Sci. 1994 Nov. 35(12):4008-14. [Medline].

  7. Fukuchi T, Yue BY, Sugar J, Lam S. Lysosomal enzyme activities in conjunctival tissues of patients with keratoconus. Arch Ophthalmol. 1994 Oct. 112(10):1368-74. [Medline].

  8. Kenney MC, Nesburn AB, Burgeson RE, Butkowski RJ, Ljubimov AV. Abnormalities of the extracellular matrix in keratoconus corneas. Cornea. 1997 May. 16(3):345-51. [Medline].

  9. Behndig A, Karlsson K, Johansson BO, Brännström T, Marklund SL. Superoxide dismutase isoenzymes in the normal and diseased human cornea. Invest Ophthalmol Vis Sci. 2001 Sep. 42(10):2293-6. [Medline].

  10. Zadnik K, Barr JT, Edrington TB, et al. Baseline findings in the Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study. Invest Ophthalmol Vis Sci. 1998 Dec. 39(13):2537-46. [Medline].

  11. Buddi R, Lin B, Atilano SR, Zorapapel NC, Kenney MC, Brown DJ. Evidence of oxidative stress in human corneal diseases. J Histochem Cytochem. 2002 Mar. 50(3):341-51. [Medline].

  12. Cristina Kenney M, Brown DJ. The cascade hypothesis of keratoconus. Cont Lens Anterior Eye. 2003 Sep. 26(3):139-46. [Medline].

  13. Sherwin T, Brookes NH. Morphological changes in keratoconus: pathology or pathogenesis. Clin Experiment Ophthalmol. 2004 Apr. 32(2):211-7. [Medline].

  14. Woodward MA, Blachley TS, Stein JD. The Association Between Sociodemographic Factors, Common Systemic Diseases, and Keratoconus: An Analysis of a Nationwide Heath Care Claims Database. Ophthalmology. 2015 Dec 16. [Medline].

  15. Atilano SR, Coskun P, Chwa M, Jordan N, Reddy V, Le K. Accumulation of mitochondrial DNA damage in keratoconus corneas. Invest Ophthalmol Vis Sci. 2005 Apr. 46(4):1256-63. [Medline].

  16. Kenney MC, Chwa M, Atilano SR, Tran A, Carballo M, Saghizadeh M. Increased levels of catalase and cathepsin V/L2 but decreased TIMP-1 in keratoconus corneas: evidence that oxidative stress plays a role in this disorder. Invest Ophthalmol Vis Sci. 2005 Mar. 46(3):823-32. [Medline].

  17. Meek KM, Tuft SJ, Huang Y, Gill PS, Hayes S, Newton RH, et al. Changes in collagen orientation and distribution in keratoconus corneas. Invest Ophthalmol Vis Sci. 2005 Jun. 46(6):1948-56. [Medline].

  18. Määttä M, Heljasvaara R, Sormunen R, Pihlajaniemi T, Autio-Harmainen H, Tervo T. Differential expression of collagen types XVIII/endostatin and XV in normal, keratoconus, and scarred human corneas. Cornea. 2006 Apr. 25(3):341-9. [Medline].

  19. Määttä M, Väisänen T, Väisänen MR, Pihlajaniemi T, Tervo T. Altered expression of type XIII collagen in keratoconus and scarred human cornea: Increased expression in scarred cornea is associated with myofibroblast transformation. Cornea. 2006 May. 25(4):448-53. [Medline].

  20. Ku JY, Niederer RL, Patel DV, Sherwin T, McGhee CN. Laser scanning in vivo confocal analysis of keratocyte density in keratoconus. Ophthalmology. 2008 May. 115(5):845-50. [Medline].

  21. Lema I, Durán JA. Inflammatory molecules in the tears of patients with keratoconus. Ophthalmology. 2005 Apr. 112(4):654-9. [Medline].

  22. Lema I, Durán JA, Ruiz C, Díez-Feijoo E, Acera A, Merayo J. Inflammatory response to contact lenses in patients with keratoconus compared with myopic subjects. Cornea. 2008 Aug. 27(7):758-63. [Medline].

  23. Millodot M, Ortenberg I, Lahav-Yacouel K, Behrman S. Effect of ageing on keratoconic corneas. J Optom. 2015 Jun 30. [Medline].

  24. Dienes L, Kiss HJ, Perényi K, Nagy ZZ, Acosta MC, Gallar J, et al. Corneal Sensitivity and Dry Eye Symptoms in Patients with Keratoconus. PLoS One. 2015. 10 (10):e0141621. [Medline].

  25. Aldave AJ, Ann LB, Frausto RF, Nguyen CK, Yu F, Raber IM. Classification of posterior polymorphous corneal dystrophy as a corneal ectatic disorder following confirmation of associated significant corneal steepening. JAMA Ophthalmol. 2013 Dec. 131 (12):1583-90. [Medline].

  26. Gupta PK, Stinnett SS, Carlson AN. Prevalence of sleep apnea in patients with keratoconus. Cornea. 2012 Jun. 31(6):595-9. [Medline].

  27. Macsai MS, Varley GA, Krachmer JH. Development of keratoconus after contact lens wear. Patient characteristics. Arch Ophthalmol. 1990 Apr. 108(4):534-8. [Medline].

  28. Li X, Yang H, Rabinowitz YS. Keratoconus: classification scheme based on videokeratography and clinical signs. J Cataract Refract Surg. 2009 Sep. 35 (9):1597-603. [Medline].

  29. Rabinowitz YS, Li X, Canedo AL, Ambrósio R Jr, Bykhovskaya Y. Optical coherence tomography combined with videokeratography to differentiate mild keratoconus subtypes. J Refract Surg. 2014 Feb. 30 (2):80-7. [Medline].

  30. Steinberg J, Aubke-Schultz S, Frings A, Hülle J, Druchkiv V, Richard G, et al. Correlation of the KISA% index and Scheimpflug tomography in 'normal', 'subclinical', 'keratoconus-suspect' and 'clinically manifest' keratoconus eyes. Acta Ophthalmol. 2015 May. 93 (3):e199-207. [Medline].

  31. Zadnik K, Barr JT, Gordon MO, Edrington TB. Biomicroscopic signs and disease severity in keratoconus. Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study Group. Cornea. 1996 Mar. 15(2):139-46. [Medline].

  32. Wagner H, Barr JT, Zadnik K. Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study: methods and findings to date. Cont Lens Anterior Eye. 2007 Sep. 30(4):223-32. [Medline].

  33. Zadnik K, Barr JT, Gordon MO, Edrington TB. Biomicroscopic signs and disease severity in keratoconus. Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study Group. Cornea. 1996 Mar. 15(2):139-46. [Medline].

  34. Ridley F. EYE-RUBBING AND CONTACT LENSES. Br J Ophthalmol. 1961 Sep. 45(9):631. [Medline].

  35. Karseras AG, Ruben M. Aetiology of keratoconus. Br J Ophthalmol. 1976 Jul. 60(7):522-5. [Medline].

  36. Mathew JH, Goosey JD, Söderberg PG, Bergmanson JP. Lamellar changes in the keratoconic cornea. Acta Ophthalmol. 2015 Dec. 93 (8):767-73. [Medline].

  37. Jaynes J, Weissman BA, Edrington T. Predicting scleral GP lens entrapped tear layer oxygen tensions. Cont Lens Anterior Eye. 2015 Oct. 38 (5):392. [Medline].

  38. Rabinowitz YS. The genetics of keratoconus. Ophthalmol Clin North Am. 2003 Dec. 16(4):607-20, vii. [Medline].

  39. Bykhovskaya Y, Li X, Epifantseva I, Haritunians T, Siscovick D, Aldave A. Variation in the lysyl oxidase (LOX) gene is associated with keratoconus in family-based and case-control studies. Invest Ophthalmol Vis Sci. 2012. 53(7):4152-7. [Medline].

  40. Nielsen K, Hjortdal J, Pihlmann M, Corydon TJ. Update on the keratoconus genetics. Acta Ophthalmol. 2012 Apr 4. [Medline].

  41. Chang CY, Hersh PS. Corneal collagen cross-linking: a review of 1-year outcomes. Eye Contact Lens. 2014 Nov. 40 (6):345-52. [Medline].

  42. Tomita M, Mita M, Huseynova T. Accelerated versus conventional corneal collagen crosslinking. J Cataract Refract Surg. 2014 Jun. 40 (6):1013-20. [Medline].

  43. Acar BT, Utine CA, Ozturk V, Acar S, Ciftci F. Can the effect of transepithelial corneal collagen cross-linking be improved by increasing the duration of topical riboflavin application? An in vivo confocal microscopy study. Eye Contact Lens. 2014 Jul. 40 (4):207-12. [Medline].

  44. Wittig-Silva C, Chan E, Islam FM, Wu T, Whiting M, Snibson GR. A randomized, controlled trial of corneal collagen cross-linking in progressive keratoconus: three-year results. Ophthalmology. 2014 Apr. 121 (4):812-21. [Medline].

  45. Sherif AM, Ammar MA, Mostafa YS, Gamal Eldin SA, Osman AA. One-Year Results of Simultaneous Topography-Guided Photorefractive Keratectomy and Corneal Collagen Cross-Linking in Keratoconus Utilizing a Modern Ablation Software. J Ophthalmol. 2015. 2015:321953. [Medline].

  46. Ferenczy PA, Dalcegio M, Koehler M, Pereira TS, Moreira H, Luciane Bugmann M. Femtosecond-assisted intrastromal corneal ring implantation for keratoconus treatment: a comparison with crosslinking combination. Arq Bras Oftalmol. 2015 Mar-Apr. 78 (2):76-81. [Medline].

  47. Alnawaiseh M, Rosentreter A, Eveslage M, Eter N, Zumhagen L. Changes in Corneal Transparency After Cross-linking for Progressive Keratoconus: Long-term Follow-up. J Refract Surg. 2015 Sep. 31 (9):614-8. [Medline].

  48. Tuft SJ, Hassan H, George S, Frazer DG, Willoughby CE, Liskova P. Keratoconus in 18 pairs of twins. Acta Ophthalmol. 2012 Sep. 90(6):e482-6. [Medline].

  49. Farjadnia M, Naderan M. Corneal cross-linking treatment of keratoconus. Oman J Ophthalmol. 2015 May-Aug. 8 (2):86-91. [Medline].

  50. Shalchi Z, Wang X, Nanavaty MA. Safety and efficacy of epithelium removal and transepithelial corneal collagen crosslinking for keratoconus. Eye (Lond). 2015 Jan. 29 (1):15-29. [Medline].

  51. Kymionis GD, Bouzoukis DI, Diakonis VF, Portaliou DM, Pallikaris AI, Yoo SH. Diffuse lamellar keratitis after corneal crosslinking in a patient with post-laser in situ keratomileusis corneal ectasia. J Cataract Refract Surg. 2007 Dec. 33 (12):2135-7. [Medline].

  52. Ferrari G, Iuliano L, Viganò M, Rama P. Impending corneal perforation after collagen cross-linking for herpetic keratitis. J Cataract Refract Surg. 2013 Apr. 39 (4):638-41. [Medline].

  53. Sharma A, Nottage JM, Mirchia K, Sharma R, Mohan K, Nirankari VS. Persistent corneal edema after collagen cross-linking for keratoconus. Am J Ophthalmol. 2012 Dec. 154 (6):922-926.e1. [Medline].

  54. van Dijk K, Liarakos VS, Parker J, Ham L, Lie JT, Groeneveld-van Beek EA, et al. Bowman layer transplantation to reduce and stabilize progressive, advanced keratoconus. Ophthalmology. 2015 May. 122 (5):909-17. [Medline].

  55. Reddy JC, Hammersmith KM, Nagra PK, Rapuano CJ. The role of penetrating keratoplasty in the era of selective lamellar keratoplasty. Int Ophthalmol Clin. 2013 Spring. 53 (2):91-101. [Medline].

  56. Wisse RP, van den Hoven CM, Van der Lelij A. Does lamellar surgery for keratoconus experience the popularity it deserves?. Acta Ophthalmol. 2014 Aug. 92 (5):473-7. [Medline].

  57. Coster DJ, Lowe MT, Keane MC, Williams KA, Australian Corneal Graft Registry Contributors. A comparison of lamellar and penetrating keratoplasty outcomes: a registry study. Ophthalmology. 2014 May. 121 (5):979-87. [Medline].

  58. Arnalich-Montiel F, Alió Del Barrio JL, Alió JL. Corneal surgery in keratoconus: which type, which technique, which outcomes?. Eye Vis (Lond). 2016. 3:2. [Medline].

  59. Lowe MT, Keane MC, Coster DJ, Williams KA. The outcome of corneal transplantation in infants, children, and adolescents. Ophthalmology. 2011 Mar. 118 (3):492-7. [Medline].

  60. Pramanik S, Musch DC, Sutphin JE, Farjo AA. Extended long-term outcomes of penetrating keratoplasty for keratoconus. Ophthalmology. 2006 Sep. 113 (9):1633-8. [Medline].

  61. Moodaley LC, Woodward EG, Liu CS, Buckley RJ. Life expectancy in keratoconus. Br J Ophthalmol. 1992 Oct. 76(10):590-1. [Medline]. [Full Text].

  62. Yeung KK et al. Where have all the keratoconics gone?. Int Cont Lens Clin. 1998. 25(4):109-13.

  63. Georgiou T, Funnell CL, Cassels-Brown A, O'Conor R. Influence of ethnic origin on the incidence of keratoconus and associated atopic disease in Asians and white patients. Eye (Lond). 2004 Apr. 18(4):379-83. [Medline].

  64. Alió JL, Shabayek MH. Corneal higher order aberrations: a method to grade keratoconus. J Refract Surg. 2006 Jun. 22(6):539-45. [Medline].

  65. American Academy of Ophthalmology 2013 Annual Meeting. Presented November 16, 2013.

  66. Colin J, Malet FJ. Intacs for the correction of keratoconus: two-year follow-up. J Cataract Refract Surg. 2007 Jan. 33(1):69-74. [Medline].

  67. Fontana L, Parente G, Tassinari G. Clinical outcomes after deep anterior lamellar keratoplasty using the big-bubble technique in patients with keratoconus. Am J Ophthalmol. 2007 Jan. 143(1):117-124. [Medline].

  68. Goodman A. Crosslinking safe in children, adolescents with keratoconus. Medscape Medical News. November 28, 2013. Available at http://www.medscape.com/viewarticle/815184. Accessed: December 7, 2013.

  69. Jafri B, Li X, Yang H, Rabinowitz YS. Higher order wavefront aberrations and topography in early and suspected keratoconus. J Refract Surg. 2007 Oct. 23(8):774-81. [Medline].

  70. Kelly TL, Williams KA, Coster DJ. Corneal transplantation for keratoconus: a registry study. Arch Ophthalmol. 2011 Jun. 129(6):691-7. [Medline].

  71. Kosaki R, Maeda N, Bessho K, Hori Y, Nishida K, Suzaki A. Magnitude and orientation of Zernike terms in patients with keratoconus. Invest Ophthalmol Vis Sci. 2007 Jul. 48(7):3062-8. [Medline].

  72. Kymionis GD, Portaliou DM, Kounis GA, Limnopoulou AN, Kontadakis GA, Grentzelos MA. Simultaneous topography-guided photorefractive keratectomy followed by corneal collagen cross-linking for keratoconus. Am J Ophthalmol. 2011 Nov. 152(5):748-55. [Medline].

  73. Rabinowitz YS. Intacs for keratoconus. Curr Opin Ophthalmol. 2007 Jul. 18(4):279-83. [Medline].

  74. Raiskup-Wolf F, Hoyer A, Spoerl E, Pillunat LE. Collagen crosslinking with riboflavin and ultraviolet-A light in keratoconus: long-term results. J Cataract Refract Surg. 2008 May. 34(5):796-801. [Medline].

  75. Schlegel Z, Hoang-Xuan T, Gatinel D. Comparison of and correlation between anterior and posterior corneal elevation maps in normal eyes and keratoconus-suspect eyes. J Cataract Refract Surg. 2008 May. 34(5):789-95. [Medline].

  76. Shimmura S, Tsubota K. Deep anterior lamellar keratoplasty. Curr Opin Ophthalmol. 2006 Aug. 17(4):349-55. [Medline].

  77. Sorbara L, Dalton K. The use of video-keratoscopy in predicting contact lens parameters for keratoconic fitting. Cont Lens Anterior Eye. 2010 Jun. 33(3):112-8. [Medline].

  78. Weissman B, Chun MW, Barnhart LA. Corneal abrasion associated with contact lens correction of keratoconus--a retrospective study. Optom Vis Sci. 1994 Nov. 71(11):677-81. [Medline].

 
Previous
Next
 
An optic section of a keratoconic cornea shows corneal thinning. Vogt striae and some scarring can also be seen centrally; superiorly, a small (brown) section of the Fleischer ring is noted.
The fluorescein pattern of a rather flat-fitted rigid contact lens on an advanced keratoconic cornea.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.